Biocept Inc

NASDAQ:BIOCUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. It provides blood-based liquid biopsy technology.

Contact Information

Headquarters

9955 Mesa Rim RoadSAN DIEGO, CA, United States 92121

Phone

858-320-8200

Fax

858-320-8225

Executives

Chairman of the Board, Interim President and Chief Executive Officer

Samuel Riccitelli

Interim Chief Financial Officer, Director

Antonino Morales

Chief Operating Officer

Philippe Marchand

Senior Vice President, Chief Compliance Officer, Chief Legal Officer

Darrell Taylor

Senior Vice President - Corporate Development

Michael Terry